BR112021026554A2 - Antagonista de neurocinina-1 - Google Patents
Antagonista de neurocinina-1Info
- Publication number
- BR112021026554A2 BR112021026554A2 BR112021026554A BR112021026554A BR112021026554A2 BR 112021026554 A2 BR112021026554 A2 BR 112021026554A2 BR 112021026554 A BR112021026554 A BR 112021026554A BR 112021026554 A BR112021026554 A BR 112021026554A BR 112021026554 A2 BR112021026554 A2 BR 112021026554A2
- Authority
- BR
- Brazil
- Prior art keywords
- neurokinin
- antagonist
- formula
- compound represented
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910572272 | 2019-06-28 | ||
| CN201911375262 | 2019-12-27 | ||
| PCT/CN2020/098460 WO2020259675A1 (zh) | 2019-06-28 | 2020-06-28 | 神经激肽-1拮抗剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026554A2 true BR112021026554A2 (pt) | 2022-05-24 |
Family
ID=74059657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026554A BR112021026554A2 (pt) | 2019-06-28 | 2020-06-28 | Antagonista de neurocinina-1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12421260B2 (https=) |
| EP (1) | EP3991730A4 (https=) |
| JP (2) | JP7702887B2 (https=) |
| KR (1) | KR102940508B1 (https=) |
| CN (2) | CN113905735B (https=) |
| AU (1) | AU2020308397B2 (https=) |
| BR (1) | BR112021026554A2 (https=) |
| CA (1) | CA3144247A1 (https=) |
| MX (1) | MX2021015827A (https=) |
| TW (1) | TWI853965B (https=) |
| WO (1) | WO2020259675A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021407138A1 (en) * | 2020-12-25 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist |
| CN114671913A (zh) * | 2020-12-25 | 2022-06-28 | 上海盛迪医药有限公司 | 一种神经激肽-1拮抗剂的晶型及其制备方法 |
| JP2025500688A (ja) * | 2022-01-12 | 2025-01-09 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ニューロキニン－１アンタゴニストプロドラッグ化合物の医薬組成物 |
| CN118475589A (zh) | 2022-01-12 | 2024-08-09 | 江苏恒瑞医药股份有限公司 | 一种神经激肽-1拮抗剂前药化合物的晶型 |
| CN119528985A (zh) | 2023-08-28 | 2025-02-28 | 科睿迪(南京)医药科技有限公司 | 神经激肽-1受体拮抗剂化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU678409B2 (en) | 1992-10-28 | 1997-05-29 | Merck Sharp & Dohme Limited | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| US5661162A (en) | 1992-12-14 | 1997-08-26 | Merck Sharp & Dohme Limited | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists |
| ES2120170T3 (es) | 1994-01-13 | 1998-10-16 | Merck Sharp & Dohme | Antagonistas azaciclicos gem-disustituidos de taquiquininas. |
| WO1998022542A2 (en) * | 1996-11-08 | 1998-05-28 | Ikonos Corporation | Chemical functionalization of surfaces |
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| CN1678317B (zh) * | 2002-07-03 | 2010-10-27 | 先灵公司 | 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽-1(nk-1)拮抗剂的1-酰氨基-4-苯基-4-苄氧基甲基-哌啶衍生物和相关化合物 |
| AR046769A1 (es) * | 2003-12-22 | 2005-12-21 | Schering Corp | Composiciones farmaceuticas |
| CN102573475B (zh) * | 2009-08-14 | 2016-01-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| CA3123900A1 (en) * | 2011-07-28 | 2013-01-31 | Kempharm Inc. | Methylphenidate-prodrugs, processes of making and using the same |
| CN102775401B (zh) | 2012-08-15 | 2015-01-07 | 青岛农业大学 | 一种美洛昔康的合成方法 |
| CN108148060B (zh) * | 2016-12-05 | 2020-06-19 | 四川科伦博泰生物医药股份有限公司 | 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途 |
| CN107383008A (zh) * | 2017-08-14 | 2017-11-24 | 苏州信恩医药科技有限公司 | 一种罗拉匹坦的合成方法 |
-
2020
- 2020-06-28 JP JP2021577929A patent/JP7702887B2/ja active Active
- 2020-06-28 BR BR112021026554A patent/BR112021026554A2/pt unknown
- 2020-06-28 AU AU2020308397A patent/AU2020308397B2/en active Active
- 2020-06-28 WO PCT/CN2020/098460 patent/WO2020259675A1/zh not_active Ceased
- 2020-06-28 MX MX2021015827A patent/MX2021015827A/es unknown
- 2020-06-28 KR KR1020227003091A patent/KR102940508B1/ko active Active
- 2020-06-28 CN CN202080040881.3A patent/CN113905735B/zh active Active
- 2020-06-28 CA CA3144247A patent/CA3144247A1/en active Pending
- 2020-06-28 US US17/623,205 patent/US12421260B2/en active Active
- 2020-06-28 EP EP20831251.2A patent/EP3991730A4/en active Pending
- 2020-06-28 CN CN202410285183.XA patent/CN118324811A/zh active Pending
- 2020-06-29 TW TW109121881A patent/TWI853965B/zh active
-
2025
- 2025-04-23 JP JP2025071172A patent/JP2025111616A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113905735B (zh) | 2024-03-15 |
| US12421260B2 (en) | 2025-09-23 |
| US20220380393A1 (en) | 2022-12-01 |
| TW202115064A (zh) | 2021-04-16 |
| CN113905735A (zh) | 2022-01-07 |
| MX2021015827A (es) | 2022-04-11 |
| AU2020308397B2 (en) | 2026-01-08 |
| KR20220054287A (ko) | 2022-05-02 |
| CA3144247A1 (en) | 2020-12-30 |
| JP7702887B2 (ja) | 2025-07-04 |
| EP3991730A4 (en) | 2023-08-09 |
| TWI853965B (zh) | 2024-09-01 |
| CN118324811A (zh) | 2024-07-12 |
| EP3991730A1 (en) | 2022-05-04 |
| JP2025111616A (ja) | 2025-07-30 |
| AU2020308397A1 (en) | 2022-02-17 |
| WO2020259675A1 (zh) | 2020-12-30 |
| JP2022539570A (ja) | 2022-09-12 |
| KR102940508B1 (ko) | 2026-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021026554A2 (pt) | Antagonista de neurocinina-1 | |
| BR112016023679A2 (pt) | derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos | |
| CL2018002009A1 (es) | Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. | |
| US9539256B2 (en) | Modulators of exchange proteins directly activated by cAMP (EPACS) | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| BR112022020933A2 (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| BR112022011102A2 (pt) | Tratamentos do edema macular diabético e da acuidade visual deficiente | |
| BR112021026397A2 (pt) | Antagonista de ep2 | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| MY206893A (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| US20220193017A1 (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
| BR112019018028A2 (pt) | Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| EA202190398A1 (ru) | Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4 | |
| BR112017016065A2 (pt) | prevenção ou tratamento de ácido úrico ou doença gotosa | |
| BR112022009533A2 (pt) | Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica | |
| CR20240015A (es) | COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203) | |
| PH12021550549A1 (en) | Dp antagonist | |
| BR112019018185A2 (pt) | composição para tratar uma doença de articulação humana, e, kit. | |
| MX393807B (es) | Solucion de levodopa para infusion. | |
| EA202091293A1 (ru) | Производные пиридинона и их применение в качестве селективных ингибиторов alk-2 | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| BR112022007328A2 (pt) | Uso de derivado de fenilquinolinona ou derivado de flavonóide para tratamento de dor neuropática |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |